Inactive Instrument

News Caladrius Biosciences Inc Nasdaq

Equities

US1280581042

End-of-day quote Nasdaq Other stock markets
- ^USD	-

Apr. 09	Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma	CI
Mar. 21	Sector Update: Health Care Stocks Higher in Late Afternoon Trading	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma	Apr. 09	GL
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma	Apr. 09	CI
Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events	Apr. 03	GL
Sector Update: Health Care Stocks Higher in Late Afternoon Trading	Mar. 21	MT
Sector Update: Health Care Stocks Higher in Afternoon Trading	Mar. 21	MT
Lisata Therapeutics Says FDA Grants Rare Pediatric Disease Designation to Osteosarcoma Drug	Mar. 21	MT
Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma	Mar. 21	GL
Lisata Therapeutics to Present at the Life Science Investor Forum on March 7ᵗʰ	Mar. 04	AQ
Transcript : Lisata Therapeutics, Inc., 2023 Earnings Call, Feb 29, 2024	Feb. 29
Lisata Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update	Feb. 29	GL
Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time	Feb. 22	GL
Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time	Feb. 22	AQ
Lisata Therapeutics to Present at BIO CEO & Investor Conference	Feb. 20	GL
Lisata Therapeutics to Present at the Sequire Investor Summit in Puerto Rico	Jan. 18	AQ
Lisata Therapeutics Announces First Patient Treated in the Phase 2a Trial of LSTA1 in Patients with Glioblastoma Multiforme	Jan. 17	GL
Lisata Therapeutics, Inc. Announces First Patient Treated in the Phase 2A Trial of Lsta1 in Patients with Glioblastoma Multiforme	Jan. 17	CI
Lisata Therapeutics Announces Publication of Case Report on a Complete Response in a Metastatic Gastroesophageal Adenocarcinoma Patient Treated with LSTA1 in Combination with Standard-of-Care Therapy	Jan. 04	GL
Lisata Therapeutics Announces Publication of Case Report on a Complete Response in a Metastatic Gastroesophageal Adenocarcinoma Patient Treated with LSTA1 in Combination with Standard-of-Care Therapy	Jan. 04	AQ
Lisata Therapeutics Announces Completion of Enrollment in Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma	Dec. 12	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Caladrius Biosciences Inc Nasdaq

Equities

US1280581042

Summary

Filters